Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization.
OBJECTIVE
To evaluate the therapeutic effect of intravitreal bevacizumab in patients with uveitis-associated choroidal/retinal neovascularization.


METHODS
Two female patients (40 years, 15 years) with posterior uveitis, (one presumed ocular sarcoidosis, one lupus) were evaluated for neovascularization of the posterior segment. Both patients were given a single dose of 1.25 mg intravitreal bevacizumab.


RESULTS
Significant anatomical and functional recovery was evident in both patients within a few weeks.


CONCLUSIONS
In selected uveitic patients, bevacizumab may be an option for managing neovascularization.
Kurup
Shree
S
Department of Ophthalmology, Wake Forest University Eye Centre, Winston Salem, North Carolina 27101, USA. skurup@wfubmc.edu
Lew
Julie
J
Byrnes
Gordon
G
Yeh
Steven
S
Nussenblatt
Robert
R
Levy-Clarke
Grace
G
D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D006801:Humans; D007267:Injections; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D016896:Treatment Outcome; D014602:Uvea / Q000098:blood supply*; D014605:Uveitis / Q000150:complications*; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab